GO Therapeutics is a pioneering brand dedicated to developing cancer therapeutics specifically designed for solid tumors. By harnessing the unique aspects of cancer cell biology, GO Therapeutics is revolutionizing the treatment of previously intractable tumors. They target O-linked glycoproteins that are specific to cancer cells, enabling them to develop proprietary, high-affinity antibodies that specifically target novel cancer-specific markers.

These antibodies serve as the foundation for a wide range of highly effective cancer-killing modalities, including T-cell bispecifics, CAR-T, and ADCs. The key focus of GO Therapeutics is to ensure that each antibody selectively eliminates cancer cells while sparing healthy tissue. By integrating their cutting-edge cancer-specific therapeutics into combination therapies, GO Therapeutics is transforming the landscape of cancer treatment.

Their mission is to usher in a new era of cancer therapeutics that are highly efficacious and safe. Welcome to the next-generation immuno-oncology with GO Therapeutics. For more information, please visit their website and get in touch